ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: FR-PO428

High Repeatability and Sensitivity of MR Imaging Biomarkers of CKD

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Hockings, Paul, Antaros Medical, Molndal, Sweden
  • Makvandi, Kianoush, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Unnerstall, Tim, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Leonhardt, Henrik, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Frödén löwenmark, Anna, Antaros Medical, Molndal, Sweden
  • Jarl, Lisa, Antaros Medical, Molndal, Sweden
  • Englund, Camilla, Antaros Medical, Molndal, Sweden
  • Francis, Susan, Sir Peter Mansfield Magnetic Resonance Center,, Nottingham, United Kingdom
  • Jensen, Gert, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Erlandsson, Fredrik, AstraZeneca, Gaithersburg, Maryland, United States
  • Sundgren andersson, Anna K., AstraZeneca, Gaithersburg, Maryland, United States
  • Hulthe, Johannes, Antaros Medical, Molndal, Sweden
  • Baid-Agrawal, Seema, Sahlgrenska University Hospital, Gothenburg, Sweden

New drug development tools are needed for monitoring response to therapy in chronic kidney disease (CKD) with increased precision and repeatability. We evaluated 18 CKD4 and 10 CKD3 subjects with type 2 diabetic nephropathy, and 20 age- and sex-matched healthy volunteers with a wide range of non-contrast magnetic resonance Imaging (MRI) techniques. Measured GFR (mGFR) was assessed using iohexol clearance. Half of the subjects were re-scanned after 2-4 weeks to assess repeatability.


MRI techniques included R2* for assessment of renal hypoxia, apparent diffusion coefficient (ADC) for fibrosis, R1for interstitial water balance, arterial spin labelling (ASL) for cortical perfusion, renal artery blood flow (peak systolic velocity, end diastolic velocity, mean arterial flow, and renal artery resistive index (RARI)), global perfusion (mean arterial flow/kidney volume), and kidney volume corrected for body surface area.


see Table


Several MR parameters correlate strongly with mGFR indicating that these biomarkers are biologically relevant while providing additional information on pathophysiology. Given the known relationship between MRI biomarkers and mGFR plus the intra-subject CoV, the number of subjects needed to detect, e.g. a 2 ml/min/1.73m2 change in mGFR can be calculated. To conclude, a 30 min non-contrast MRI protocol characterising important aspects of CKD with a high repeatability and sensitivity was identified. Repeatability data allows future CKD intervention studies to be correctly powered.

 Healthy ControlsCKD Stage 3CKD Stage 4Correlation with mGFR (r)p-value of correlationCoefficient of variation
R2* cortex (s-1)18.0 (1.4)17.6 (1.9)17.4 (1.4)0.150.330.04
R2* medulla (s-1)28.3 (3.1)24.5 (3.6)24.3 (3.9)0.440.0020.05
ADC cortex (mm2s-1 x 10-3)2.48 (0.17)2.47 (0.17)2.21 (0.24)0.440.0020.06
ADC medulla (mm2s-1 x 10-3)2.36 (0.17)2.29 (0.21)2.22 (0.22)0.290.0510.07
R1 cortex (s-1)1.10 (0.17)0.97 (0.23)0.97 (0.18)0.360.0110.08
R1 medulla (s-1)0.69 (0.03)0.73 (0.04)0.74 (0.09)0.380.0080.06
ASL perfusion cortex (ml/100g/min)206 (65)99 (63)76 (59)0.65<.00010.28
Peak systolic velocity (cm/s)54.3 (8.3)60.7 (18.2)42.1 (11.2)0.350.0150.09
End diastolic velocity (cm/s)17.0 (3.9)10.9 (2.4)6.39 (2.26)0.81<.00010.11
RARI0.68 (0.06)0.81 (0.05)0.84 (0.06)0.79<.00010.03
Mean arterial flow (ml/s)0.43 (1.76)6.31 (1.50)4.15 (1.24)0.86<.00010.07
Global Perfusion (ml/100g/min)436 (59)346 (53)248 (85)0.76<.00010.08
Kidney volume (ml)66.5 (9.6)56.6 (18.4)52.5 (11.5)0.4480.0010.06

mean (SD)


  • Commercial Support –